Company Performance - Graham reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.25 per share, and up from $0.33 per share a year ago, representing an earnings surprise of +80.00% [1] - The company achieved revenues of $55.49 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.57% and increasing from $49.95 million year-over-year [2] - Over the last four quarters, Graham has consistently surpassed consensus EPS estimates and topped revenue estimates three times [2] Stock Movement and Outlook - Graham shares have increased approximately 29.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] - The future performance of Graham's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $58.6 million, and for the current fiscal year, it is $1.23 on revenues of $230.3 million [7] Industry Context - The Manufacturing - General Industrial industry, to which Graham belongs, is currently ranked in the top 16% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Graham's stock performance [5][6]

分组1 - DuPont de Nemours reported quarterly earnings of $1.12 per share, exceeding the Zacks Consensus Estimate of $1.06 per share, and up from $0.97 per share a year ago, representing an earnings surprise of +5.66% [1] - The company posted revenues of $3.26 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.30%, and compared to year-ago revenues of $3.17 billion [2] - DuPont de Nemours has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed the market, losing about 7% since the beginning of the year, while the S&P 500 gained 7.6% [3] - The current consensus EPS estimate for the coming quarter is $1.13 on revenues of $3.25 billion, and for the current fiscal year, it is $4.28 on revenues of $12.72 billion [7] - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 7% of over 250 Zacks industries, indicating potential challenges for the sector [8]

Gladstone Capital (GLAD) came out with quarterly earnings of $0.5 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.57 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this real estate investment trust would post earnings of $0.5 per share when it actually produced earnings of $0.5, delivering no surprise. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in ...

This quarterly report represents an earnings surprise of -14.15%. A quarter ago, it was expected that this operator of an online marketplace and payments system in Latin America would post earnings of $7.67 per share when it actually produced earnings of $9.74, delivering a surprise of +26.99%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. MercadoLibre (MELI) came out with quarterly earnings of $10.31 per share, missing the Zacks Consensus Estimate of $12.01 per s ...

Core Viewpoint - Atlas Energy Solutions Inc. reported break-even quarterly earnings per share, missing the Zacks Consensus Estimate of $0.14, and showing a decline from $0.16 per share a year ago, resulting in an earnings surprise of -100.00% [1] - The company has not surpassed consensus EPS estimates over the last four quarters, with revenues of $288.68 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.35% [2] Financial Performance - The company reported revenues of $288.68 million for the quarter, slightly up from $287.52 million year-over-year [2] - Atlas Energy Solutions Inc. shares have decreased by approximately 43.6% since the beginning of the year, contrasting with the S&P 500's gain of 6.1% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.13 for the coming quarter and $0.42 for the current fiscal year, with revenues expected to be $288.89 million and $1.16 billion respectively [7] - The Zacks Rank for Atlas Energy Solutions Inc. is currently 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Context - The Oil and Gas - Integrated - United States industry is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting a challenging environment for companies within this sector [8]

Company Performance - Tidewater reported quarterly earnings of $1.23 per share, significantly exceeding the Zacks Consensus Estimate of $0.28 per share, representing an earnings surprise of +339.29% [1] - The company posted revenues of $341.43 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.50% and showing a slight increase from $339.23 million in the same quarter last year [2] - Over the last four quarters, Tidewater has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Future Outlook - The sustainability of Tidewater's stock price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.20 on revenues of $350.07 million, and for the current fiscal year, it is $3.14 on revenues of $1.34 billion [7] - The estimate revisions trend for Tidewater was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Oil and Gas - Integrated - United States industry, to which Tidewater belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Tidewater's stock performance [5]

Encompass Health (EHC) came out with quarterly earnings of $1.4 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this rehabilitation hospital operator would post earnings of $1.19 per share when it actually produced earnings of $1.37, delivering a surprise of +15.13%. Over the last ...

Company Performance - CVRx reported a quarterly loss of $0.57 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.52, but an improvement from a loss of $0.65 per share a year ago, indicating a -9.62% earnings surprise [1] - The company posted revenues of $13.59 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.96% and showing an increase from $11.81 million in the same quarter last year [2] - Over the last four quarters, CVRx has surpassed consensus revenue estimates four times, but has only done so for EPS estimates once [2] Stock Performance - CVRx shares have declined approximately 40.3% since the beginning of the year, contrasting with the S&P 500's gain of 6.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.47 on revenues of $14.54 million, and for the current fiscal year, it is -$1.97 on revenues of $56.54 million [7] Industry Outlook - The Medical - Instruments industry, to which CVRx belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of CVRx's stock may be influenced by the overall outlook of the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

ZoomInfo (GTM) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +8.70%. A quarter ago, it was expected that this company would post earnings of $0.22 per share when it actually produced earnings of $0.23, delivering a surprise of +4.55%.Over the last four quarters, the company has surp ...

Group 1 - BioCryst Pharmaceuticals reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, compared to a loss of $0.06 per share a year ago, representing an earnings surprise of +400.00% [1] - The company posted revenues of $163.35 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 9.74%, and compared to year-ago revenues of $109.33 million [2] - BioCryst has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates four times during the same period [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with BioCryst shares gaining about 5.7% since the beginning of the year, compared to the S&P 500's gain of 6.1% [3] - The current consensus EPS estimate for the coming quarter is $0.06 on revenues of $155.49 million, and $0.13 on revenues of $609.2 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 32% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]